The University of Michigan Health System will begin administering palivizumab (Synagis®) respiratory syncytial virus (RSV) prophylaxis to high-risk infants starting December 1st, 2015. This starting date is based on local and statewide epidemiologic data from recent RSV seasons. In the event that local laboratory surveillance data suggest an earlier start to the RSV season the starting date may be modified.

This website will be updated in the event that the starting date occurs sooner.

UMHS Department of Pharmacy